Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07291297 · ClinicalTrials.gov registry record · Phase 2
Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma
A Phase 2 study of Sarcoma, Soft Tissue and Sarcoma Metastatic, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT07291297 is a Phase 2 study of Sarcoma, Soft Tissue and Sarcoma Metastatic that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 50 participants, below the 67-participant average among 4 other Sarcoma, Soft Tissue trials with a reported enrollment target (25% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT07291297, a Phase 2 study of Sarcoma, Soft Tissue and Sarcoma Metastatic, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research study is to see how metformin, when used in combination with standard of care (SOC) treatment for metastatic (cancer that has spread) soft tissue sarcoma can improve patient outcomes.
Conditions Studied
Interventions
- DRUG Metformin Hydrochloride ER
Study Locations (2)
North Carolina
- Levine Cancer Institute - Charlotte
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-03-04 |
| Est. Completion | 2033-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07291297
The ClinicalTrials.gov registry entry for NCT07291297 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 67-participant average among 4 other Sarcoma, Soft Tissue trials with a reported enrollment target (25% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sarcoma, Soft Tissue appearing as the primary indexed condition, and to 1 intervention - of which Metformin Hydrochloride ER is the first listed.
NCT07291297 reports 2 study locations spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT07291297 about?
NCT07291297 is a clinical study titled "Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma". The purpose of this research study is to see how metformin, when used in combination with standard of care (SOC) treatment for metastatic (cancer that has spread) soft tissue sarcoma can improve patient outcomes.
What is the current status of trial NCT07291297?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2026-03-04. Estimated completion is 2033-10.
What conditions does trial NCT07291297 study?
This clinical trial studies the following conditions: Sarcoma, Soft Tissue, Sarcoma Metastatic.
What interventions are being tested in trial NCT07291297?
The interventions under investigation include: Metformin Hydrochloride ER (DRUG).
Who is sponsoring clinical trial NCT07291297?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07291297 being conducted?
This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma, Soft Tissue
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
COMPLETED · Phase 2
-
Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma
ACTIVE NOT RECRUITING · Early Phase 1
-
Transcutaneous Oxygen as a Predictor of Wound Healing Complications in Preoperatively Radiated Soft Tissue Sarcoma
COMPLETED
-
Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.